StockData
Lexaria Bioscience Corp. logo

Lexaria Bioscience Corp. (LEXX) stock

LEXXNasdaqPharmaceutical PreparationsFiscal year ends August 31
Financials through Q3 FY2026, quarter ended May 31, 2026Last filing: 10-Q on Jul 13, 2026Score 8/30
$4.18−0.23 (-5.22%)

Close on Nov 17, 2026Market cap $103.61MP/E –Yield –

Lexaria Bioscience pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Lexaria Bioscience's pe ratio was 93.9× on Sep 30, 2020, against 73.7× a year earlier. Over the last 2 years it ranged from 73.7× to 266.1×, with a median of 138.9×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2020Sep 30, 202093.9×−16.4
2019Dec 31, 2019110.3×−49.4
2018Dec 31, 2018159.7×–

More Lexaria Bioscience figures

See a number that looks wrong?